# US 2021/0332120 A1 · Trispecific antibodies against il-17a, il-17f and other pro-inflammatory molecule

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0332120 A1
- Document ID: US20210332120A1
- Status: Published application
- Kind: A1
- Application number: 16/097,562
- Filed: 2016-12-02
- Published: 2021-10-28
- Earliest claimed: 2016-04-29
- Assignees: Joint Stock Company “Biocad”
- Applicants: Joint Stock Company "Biocad"
- Inventors: Dmitry Valentinovich MOROZOV; Andrei Borisovich ULITIN; Ekaterina Sergeevna ZUBAREVA; Iakov Iurevich USTIUGOV; Aleksandr Vladimirovich KARABELSKII; Dmitry Valeryevich KORZHAVIN; Tatiana Veniaminovna CHERNOVSKAYA; Aleksandr Valerevich GRACHEV; Yury Ivanovich BASOVSKIY; Ekaterina Aleksandrovna LOMKOVA; Veronika Sergeevna USATOVA; Aleksei Aleksandrovich ALEKSANDROV; Elena Leonidovna MOROZOVA; Roman Alekseevich IVANOV; Pavel Andreevich IAKOVLEV
- Web page: https://patentgrep.com/patent/US20210332120A1

## CPC

- C07K 16/244: {Interleukins [IL]}
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 27/00: Drugs for disorders of the senses
- C07K 16/24: against cytokines, lymphokines or interferons
- C07K 16/241: {Tumor Necrosis Factors}
- C07K 16/46: Hybrid immunoglobulins (hybrids of an immunoglobulin with a peptide not being an immunoglobulin C07K19/00)
- C12N 5/10: Cells modified by introduction of foreign genetic material
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- A61K 2039/505: {comprising antibodies}
- C07K 2317/22: from camelids, e.g. camel, llama or dromedary
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/55: Fab or Fab'
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/734: Complement-dependent cytotoxicity [CDC]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to the field of biotechnology and provides monoclonal tri-specific binding molecules that specifically bind to human IL-17A, human IL-17F, and a human pro-inflammatory molecule (in particular, TNFα) with high affinity. The invention also relates to DNA constructs encoding said binding molecules, related expression vectors and methods of production, and methods of treatment using said binding molecules.

## Claims

### Claim 1

A tri-specific binding molecule comprising a first binding domain that binds to human IL-17A and human IL-17-F and a second binding domain that binds to a human pro-inflammatory molecule.

### Claim 2 (depends on 1)

The binding molecule according to claim 1, wherein said binding molecule is an antibody or an antigen-binding fragment thereof.

### Claim 3 (depends on 1)

The binding molecule according to claim 1, wherein said first binding domain comprises the amino acid sequence SEQ ID NO: 3.

### Claim 4 (depends on 1)

The binding molecule according to claim 1, wherein said first binding domain comprises amino acid sequences corresponding to SEQ ID NOs: 1-3.

### Claim 5 (depends on 1)

The binding molecule according to claim 1, wherein said first binding domain competes for binding with or binds to the same epitope as a binding domain comprising the amino acid sequence of SEQ ID NO: 4.

### Claim 6 (depends on 1)

The binding molecule according to claim 1, wherein said first binding domain is at least 90% identical to SEQ ID NO: 4.

### Claim 7 (depends on 1)

The binding molecule according to claim 1, wherein said first binding domain comprises the amino acid sequence of SEQ ID NO: 4.

### Claim 8 (depends on 1)

The binding molecule according to claim 1, wherein said first binding domain is humanized.

### Claim 9 (depends on 1)

The binding molecule according to claim 1, wherein said second binding domain binds to human TNFα.

### Claim 10 (depends on 9)

The binding molecule according to claim 9, wherein said second binding domain competes for binding with or binds to the same epitope as a binding domain comprising one of:
a) a heavy chain comprising amino acid sequences corresponding to SEQ ID NOs: 10-12 and a light chain comprising amino acid sequences corresponding to SEQ ID NOs: 13-15;
b) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 8 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 9; and
c) a heavy chain comprising the amino acid sequence of SEQ ID NO: 5 and a light chain comprising the amino acid sequence of SEQ ID NO: 6.

### Claim 11 (depends on 9)

The binding molecule according to claim 9, wherein said second binding domain comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 12 and a light chain comprising the amino acid sequence of SEQ ID NO: 15.

### Claim 12 (depends on 11)

The binding molecule according to claim 11, wherein said second binding domain comprises a heavy chain comprising amino acid sequences corresponding to SEQ ID NOs: 10-12 and a light chain comprising amino acid sequences corresponding to SEQ ID NOs: 13-15.

### Claim 13 (depends on 9)

The binding molecule according to claim 9, wherein said second binding domain comprises at least one of: a heavy chain variable domain at least 90% identical to SEQ ID NO: 8; and a variable domain at least 90% identical to SEQ ID NO: 9.

### Claim 14 (depends on 9)

The binding molecule according to claim 9, wherein said second binding domain comprises at least one of: a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 8; and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 9.

### Claim 15 (depends on 9)

The binding molecule according to claim 9, wherein said second binding domain comprises a heavy chain variable domain consisting of the amino acid sequence of SEQ ID NO: 8 and a light chain variable domain consisting of the amino acid sequence of SEQ ID NO: 9.

### Claim 16 (depends on 9)

The binding molecule according to claim 9, wherein the second binding domain is one of: a chimeric antibody; a humanized antibody; a human antibody; a single chain antibody; Fv; Fab; F(ab′)2; Fd; single chain Fv molecule (scFv); diabody; and single domain antibody (dAb).

### Claim 17 (depends on 9)

The binding molecule according to claim 9, wherein said second binding domain comprises at least one of: a heavy chain at least 90% identical to SEQ ID NO: 5; and a light chain at least 90% identical to SEQ ID NO: 6.

### Claim 18 (depends on 9)

The binding molecule according to claim 9, wherein said second binding domain comprises a heavy chain comprising at least one of: the amino acid sequence of SEQ ID NO: 5; and a light chain comprising the amino acid sequence of SEQ ID NO: 6.

### Claim 19 (depends on 9)

The binding molecule according to claim 9, wherein said second binding domain comprises a heavy chain consisting of the amino acid sequence of SEQ ID NO: 5 and a light chain consisting of the amino acid sequence of SEQ ID NO: 6.

### Claim 20

A tri-specific binding molecule comprising a first binding domain that binds to human IL-17A and human IL-17F and a second binding domain that binds to human TNFα, wherein said first binding domain comprises the amino acid sequence of SEQ ID NO: 4 and said second binding domain comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 5 and a light chain comprising the amino acid sequence of SEQ ID NO: 6.

### Claim 21

A tri-specific binding molecule that binds to human IL-17A, human IL-17F, and human TNFα, wherein said binding molecule comprises amino acid sequences corresponding to SEQ ID NOs: 5 and 7.

### Claim 22 (depends on 1)

The binding molecule according to claim 1, wherein said first binding domain and said second binding domain are joined by a peptide linker of greater than five amino acids.

### Claim 23 (depends on 22)

The binding molecule according to claim 22, wherein the amino acid residues of the peptide linker are selected from G, A, S, P, E, T, D, and K.

### Claim 24 (depends on 22)

The binding molecule according to claim 22, wherein the peptide linker comprises the amino acid sequence of SEQ ID NO: 16.

### Claim 25 (depends on 1)

The binding molecule according to claim 1, wherein said binding molecule is an antibody of isotype IgG or an antigen-binding fragment thereof.

### Claim 26 (depends on 25)

The binding molecule according to claim 25, wherein said antibody is of isotype subtype IgG1.

### Claim 27

(canceled)

### Claim 28

(canceled)

### Claim 29 (depends on 1)

A pharmaceutical composition comprising the binding molecule according to claim 1 and a pharmaceutically acceptable excipient.

### Claim 30 (depends on 3)

An isolated nucleic acid molecule comprising a nucleotide sequence that encodes the first binding domain of the binding molecule according to claim 3.

### Claim 31 (depends on 11)

An isolated nucleic acid molecule comprising a nucleotide sequence that encodes the heavy chain, the light chain, or both, of the second binding domain of the binding molecule according to claim 11.

### Claim at position 32

32-38. (canceled)

### Claim 39 (depends on 1, 29)

A method for treating a patient in need thereof, comprising administering to the patient the binding molecule according to claim 1, or the pharmaceutical composition according to claim 29.

### Claim 40 (depends on 39)

The method according to claim 39, wherein the patient has a disorder mediated by IL-17A, IL-17F, or TNFα.

### Claim 41 (depends on 1, 29)

A method for treating rheumatoid arthritis, psoriasis, or psoriatic arthritis in a patient, comprising administering to said patient the binding molecule according to claim 1 or the pharmaceutical composition according to claim 29.

### Claim 42 (depends on 41)

The method according to claim 41, wherein said method further comprises administering an anti-inflammatory or immunosuppressive agent.

### Claim 43

(canceled)
